Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

San Antonio, Texas

Cancer biologic therapy trials in San Antonio, TX

35 cancer biologic therapy studies are recruiting participants at sites in San Antonio as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Antonio at a glance

  • 35 studies are recruiting at a site in San Antonio.
  • By phase: Phase 1 (11), Phase 1/2 (3), Phase 2 (9), Phase 3 (12).
  • By sponsor: industry (27), government (6), university, hospital or other (2).
  • By research area: Breast Cancer (14), Lymphoma (14), Lung Cancer (3), Pancreatic Cancer (2), Melanoma (1), Prostate Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in San Antonio

Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mays Cancer Center ( Site 0122)
    Registry record
    NCT06393374 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8001)
    Registry record
    NCT06841354 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8004)
    Registry record
    NCT06966700 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT06058377 · updated
  5. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    START San Antonio
    Registry record
    NCT07652242 · updated
  6. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mays Cancer Center ( Site 0049)
    Registry record
    NCT07060807 · updated
  7. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Nammi Therapeutics Inc
    Study site
    START San Antonio
    Registry record
    NCT06582017 · updated
  8. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8002)
    Registry record
    NCT06312176 · updated
  9. A Study of PHST001 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheast Therapeutics
    Study sites
    START Center for Cancer Research - San Antonio · University of Texas (UT) Health
    Registry record
    NCT06840886 · updated
  10. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BriaCell Therapeutics Corporation
    Study sites
    Texas Oncology - San Antonio Northeast · Texas Oncology - San Antonio Stone Oak · Texas Oncology-San Antonio Cancer Care
    Registry record
    NCT06072612 · updated
  11. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Greenwich LifeSciences, Inc.
    Study sites
    Texas Oncology - San Antonio Medical Center · The University of Texas Health Sciences Center at San Antonio - Mays Cancer Center
    Registry record
    NCT05232916 · updated
  12. IDOV-Immune for Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    ViroMissile, Inc.
    Study site
    South Texas Accelerated Research Therapeutics
    Registry record
    NCT06910657 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in San Antonio

  1. M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    NEXT Oncology
    Registry record
    NCT07166601 · updated
  2. DBC-664 in Adult Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Duboce Biopharmaceuticals, Inc.
    Study site
    START San Antonio
    Registry record
    NCT07705035 · updated
  3. Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Hope Biosciences LLC
    Study site
    The University of Texas Health Science at San Antonio
    Registry record
    NCT05951777 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in San Antonio

  1. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Juri Biosciences, Inc.
    Study site
    START San Antonio
    Registry record
    NCT07824349 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Melanoma studies recruiting in San Antonio

  1. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    ModernaTX, Inc.
    Study site
    START San Antonio
    Registry record
    NCT06880549 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Antonio, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in San Antonio

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT06337318 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Methodist Children's Hospital
    Registry record
    NCT06173518 · updated
  4. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8009)
    Registry record
    NCT06890884 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT05675410 · updated
  7. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Texas Transplant Institute
    Registry record
    NCT07188558 · updated
  8. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Texas Transplant Institute
    Registry record
    NCT06500273 · updated
  9. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT05890352 · updated
  10. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT06124157 · updated
  11. A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    • Phase 2
    • From 6 months
    • All sexes
    Sponsor
    Allotera Therapeutics
    Study site
    Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
    Registry record
    NCT06514794 · updated
  12. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study sites
    Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Antonio, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in San Antonio

  1. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.

Ask about studies near San Antonio

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call